The Danish pharmaceutical company behind obesity drug Wegovy, Novo Nordisk, plans to invest US$1.09bn in expanding its ...

Novo Nordisk, the producer of Ozempic, Wegovy and other medications, will invest 6.4 billion reais ($1.09 billion) in Brazil ...

Novo Nordisk (NVO), the company behind Ozempic and Wegovy, announced that it will invest 6.4 billion reais (about $1.09 ...

Novo Nordisk is shaking up its executive team as it bids adieu to its longtime head of commercial strategy and corporate affairs. Camilla Sylvest is stepping down after a whopping 28 years at the ...

Novo Nordisk (NYSE:NVO)) is going big in Brazil. The drugmaker behind Ozempic and Wegovy just dropped a $1.09 billion investment to supercharge its manufacturing plant in Montes Claros.

LONDON/COPENHAGEN, April 3 (Reuters) - Novo Nordisk's (NOVOb.CO), opens new tab head of commercial strategy and corporate affairs, Camilla Sylvest, has decided to leave the company, the Danish ...

Shares of Novo Nordisk slipped in Monday morning trading after the company announced results of its latest weight-loss drug trial. Novo's results from its Redefine 2 late-stage trial of ...

Well before market open that morning, Morgan Stanley's Thibault Boutherin knocked his Novo Nordisk price target down to 600 Danish kroner ($86.67) per share; previously, this number was 700 kroner ...

On Monday, Novo Nordisk A/S (NYSE:NVO ... Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — this is your last chance to become ...